
    
      Total: All 689 subjects enrolled in study 103488. 23PS group: Aventis Pasteurs' 23-valent
      polysaccharide pneumococcal vaccine (Pneumovax 23) + DTPa-HBV-IPV/Hib; 10V group: GSK
      Biologicals' 10-valent pneumococcal conjugate vaccine + DTPa-HBV-IPV/Hib
    
  